iPS Cells & Regenerative Medicine– category –
-
Regeneron to Seek Approval for Hearing Loss Gene Therapy Following “Game-Changing” Clinical Data
BioPharma Dive USA Overview Regeneron plans to seek regulatory approval for its gene therapy for rare genetic hearing loss, based on "game-changing" clinical trial data published in the New England Journal of Medicine. The therapy demons... -
Axiom Unveils New Technology to Address Major Manufacturing and Quality Bottlenecks for Stem Cell Biotechs
Fierce Biotech USA Overview Axiom has announced the development of new technology addressing two major "potholes" for stem cell biotechnology companies, primarily in manufacturing scalability and quality control. This innovation is expec... -
Kolon TissueGene’s Cell and Gene Therapy TG-C Fails to Meet Primary Endpoints in Phase 3 Knee Osteoarthritis Trial
Fierce Biotech USA Overview Kolon TissueGene's cell and gene therapy TG-C failed to achieve its co-primary endpoints in the Phase 3 ACTiVION-II trial for knee osteoarthritis, showing no significant improvement in pain or function compare... -
Scribe Therapeutics Achieves $129M IPO, Targeting Cardiometabolic Diseases with Reversible Epigenetic Gene Silencing
BioPharma Dive USA Overview Scribe Therapeutics successfully completed a $129 million IPO, marking the first gene editing company to go public in over two years. The company develops an epigenetic approach that silences gene expression w... -
Eli Lilly Acquires Kelonia Therapeutics for $7 Billion, Bolstering Gene Therapy with In Vivo CAR-T Generation Technology
DCAT Value Chain Insights USA Overview Eli Lilly announced the acquisition of Kelonia Therapeutics, a clinical-stage biopharma specializing in in vivo gene delivery, for $7 billion, including $3.25 billion upfront. Kelonia's "iGPS" techn... -
Novo Nordisk Confirms 12-Month Safety and Feasibility of ESC-Derived Dopaminergic Cell Therapy for Parkinson’s in Phase 1/2 Trial
Regen Report USA Overview Novo Nordisk has announced positive 12-month safety and feasibility data from its Phase 1/2 clinical trial of embryonic stem cell (ESC)-derived dopaminergic cells for Parkinson's disease, published in Nature Med... -
Kincell Bio Scales Allogeneic Cell Therapy Manufacturing, Bridging Early Clinical to Commercial Supply
Kincell Bio USA Overview Kincell Bio, a specialized CDMO for allogeneic cell therapies, is advancing scalable manufacturing solutions to accelerate product commercialization. The company's expertise focuses on developing efficient proces... -
Global Pluripotent Stem Cell Therapies Progress to 115 Clinical Trials with Over 1,200 Patients, Demonstrating Strong Safety Profile
Vertex AI Search Global Overview Global clinical trials involving pluripotent stem cell therapies have significantly advanced, with 115 trials treating over 1,200 patients by December 2024, reporting no major safety concerns. This progre... -
iPS Cells & Regenerative Medicine Weekly Report July 19, 2026
📄 Weekly Report July 19, 2026 (PDF) — Download Weekly Report July 19, 2026 (PDF) — DownloadDownload 🎙 Podcast July 19, 2026 (MP3) — Play & Download iPS_RegenerativeMedicineEnglishPodcast_20260719.mp3Download View Past Weekly Reports→ -
MD Anderson Reports 70% Response Rate with Novel Claudin-18.2-Targeted CAR-T Cell Therapy for Intractable Kidney Cancer
MD Anderson Newsroom USA Overview Researchers at MD Anderson Cancer Center announced a 70% objective response rate (ORR) in an early-phase clinical trial of a novel CAR-T cell therapy targeting Claudin-18.2 for patients with metastatic r...
